Table 1.
Demographic and clinical characteristics of patients and controls.
| Cancer Patients (n = 249) | |||
|---|---|---|---|
| Melanoma (n = 80) | Bladder (n = 80) | Ovarian (n = 89) | |
| Sex (M/F, %M) 1 | 43/37 (53.7%) | 68/12 (85%) | 0/89 (0%) |
| Age (mean ± SD) | 60.6 ± 15.4 | 71.8 ± 10.2 | 58.7 ± 10.7 |
| Months since diagnosis (Mean ± SD) | 4.6 ± 14.5 | 14.9 ± 32.8 | 7.0 ± 19.6 |
| Histology (n) 2 | 35/45 | 36/44 | 69/20 |
| Staging (n) 3 | 51/29 | 2/78 | 26/63 |
| Treatment 4 | 10/9/61 | 51/20/9 | 32/49/8 |
| Progression (yes/no, %) | 27/80 (33.7%) | 24/80 (30.0%) | 37/89 (41.6%) |
| Death (yes/no, %) | 7/73 (8.7%) | 12/80 (15.0%) | 20/89 (22.5%) |
1 Control group: 42 healthy controls (59 ± 13.1 years, 37% males). 2 For melanoma (nodular/others), bladder (muscle invasive/superficial), ovarian (high-degree serous, undifferentiated and carcinomas/others). 3 For melanoma (Breslow’s depth <4 mm/>4 mm), bladder cancer (grade I or II/III), and ovarian carcinoma (grade I or II/III or IV). 4 For melanoma (interferon-alpha/vemurafenib/others), bladder cancer (BCG/cystectomy with or without chemotherapy/no treatment), and ovarian carcinoma (surgery + chemotherapy/neoadjuvant chemotherapy + surgery/palliative).